Auna Sa · NYSE:AUNA
Auna Sa — Q1 2026 Earnings Presentation
33 slides from Auna Sa's earnings presentation, May 20, 2026
Slide 1: Q1 2026 Earnings Call Presentation
Q1 2026 Earnings Call Presentation May │ 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 1Q'26 Highlights
1Q’26 Highlights 1Q’26 Consolidated Revenues1 +10% FXN YoY vs 1Q’25 with revenue increases across all business segments. “We got off to a 1Q’26 Adjusted EBITDA1,2 -5% FXN YoY with 18.4% margin, -2.9p.p. vs 1Q’25. strong start in Mexico increased volumes and utilization from 1Q25 and 4Q25, capitalizi
Slide 5: Strong top line across all segments and robust cash flow
Strong top line across all segments and robust cash flow Consolidated Adjusted EBITDA impacted by revenue adjustments and payroll increases in Mexico and Colombia Consolidated 1Q26 Revenue (S/) Adjusted EBITDA(1) (S/) 1,178Mn 217 Mn +13% YoY -2% YoY +10% FXN YoY -5% FXN YoY Healthcare Services Oncos
Slide 6: Q1 2026 Results by Segment
Q1 2026 Results by Segment qauna
Slide 7: Healthcare Services Mexico captures benefits of new payor tiers, ISSSTELEON pricing, growth in packages
Healthcare Services Mexico captures benefits of new payor tiers, ISSSTELEON pricing, growth in packages and private payors. Sequential QoQ Adjusted EBITDA growth of 19% with +3.6p.p. improvement in margin. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 24% of LTM Revenues 32% of L
Slide 8: Strong Peru revenue growth from Oncosalud pricing, B2B memberships and HC network sales initiatives
Strong Peru revenue growth from Oncosalud pricing, B2B memberships and HC network sales initiatives, despite revenue adjustments, which also affected Adjusted EBITDA and Adj. EBITDA margin. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 43% of LTM Revenues 46% of LTM Adj. EBITDA 2
Slide 9: Colombia expands protected lives through PGPs, now 21% of segment revenue
Colombia expands protected lives through PGPs, now 21% of segment revenue. YoY Adjusted EBITDA growth despite margin pressure from higher variable costs tied to increased volumes. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of LTM Revenues 23% of LTM Adj. EBITDA 12.2% 13.1%
Slide 10: Q1 2026 Consolidated Results
Q1 2026 Consolidated Results 10
Slide 11: Strong consolidated revenue growth across all segments validates the strategic decisions
Strong consolidated revenue growth across all segments validates the strategic decisions executed in Mexico and Colombia; Peru seizes opportunities through B2B. ▪ Mexico increased QoQ volumes: +15% in surgery and +32% in oncology. ▪ Peru adds 20,000 memberships through B2B and the HC network increas
Slide 12: Consolidated Adjusted EBITDA reflects strong revenue growth offset by payor adjustments
Consolidated Adjusted EBITDA reflects strong revenue growth offset by payor adjustments, delayed pharmacy rebates in Peru, and higher payroll expenses in Mexico and Colombia. ▪ Compensation related to new leadership and physicians in Mexico, and to minimum wage increase in Colombia. ▪ Adjusted EBITD
Slide 13: Adjusted Net Income of S/16 million, with non-cash FX losses offsetting higher operating profit
Adjusted Net Income of S/16 million, with non-cash FX losses offsetting higher operating profit, lower net interest expenses and income tax efficiencies. ▪ Non-cash FX losses mainly due to the depreciation of the Peruvian Sol below the protection range of Auna’s new hedging structure implemented at
Slide 14: Free cash flow generation expands 2.6x versus 1Q25
Free cash flow generation expands 2.6x versus 1Q25 off the back of working capital discipline and supplier financing initiatives. EoP cash grows 22% versus the end of 2025. ▪ Free cash flow includes Maintenance CapEx of S/34 million, or 3% of revenues ▪ On track to achieve 3.0x medium term leverage
Slide 15: Fortified capital structure with reduced annual interest expenses; leverage ratio impacted by non-cash FX
Fortified capital structure with reduced annual interest expenses; leverage ratio impacted by non- cash FX effects in 1Q26. Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Committed to achieving 3.0x Leverage Ratio target. Consolidated Debt: S/ 3,815 Term Loan 8% ✓ Approximately US
Slide 16: Supported by strong fundamentals across all operations, we are reaffirming our revenue and EBITDA guidance
“Supported by strong Peru continues to show significant growth potential in Healthcare plans, with fundamentals initiatives underway to offset revenue adjustments as the Trecca ambulatory tower progresses toward completion. across all Colombia is performing strongly, supported by a more balanced pay
Slide 17: Q&A
Q&A qund
Slide 18: Exhibits
Exhibits qund
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Mar-26 Δ Mar-26 Mar-26 Δ Mar-26 Mar-26 Dec-25 Mar-26 Dec-25 (USD) vs Dec-25 (USD) vs Dec-25 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 117 409 335 73
Slide 20: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 1Q'26 Δ 1Q'26 vs 1Q'26 1Q'25 (USD) 1Q'25 4Q'25 Revenue Healthcare Services Mexico 80 279 243 15% 8% Healthcare Services Colombia 114 399 339 18% 3% - Healthcare Services Colom
Slide 21: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 1Q'26 Δ 1Q'26 vs 1Q'26 1Q'25 (USD) 1Q'25 4Q'25 Share of profit of equity accounted investees 1 3 3 -8% 8% Profit (loss) before tax 5 16 62 -73% -1.2x Income tax expense (benef
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 26 Δ YTD 26 YTD 26 Δ YTD 26 YTD 26 YTD 25 YTD 26 YTD 25 (USD) vs YTD 25 (USD) vs YTD 25 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 23: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 24: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) For the three months ended March 31, 2026 Healthcare Consolidated Healthcare Healthcare Oncosalud Holding and Services Reportable Services Mexico Services P
Slide 25: Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 26: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 1Q'26 1Q'26 1Q'25 4Q'25 (USD) Net Income (Loss) 3 9 38 (64) (a) Pre-operat
Slide 27: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities. Mar-25 Mar-26 Cash generated from operating activities 159,975 236,721 (-) Inco
Slide 28: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 29: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. Mar-25 Dec-25 Mar-26 (+) Loans and borrowings 3,595 3,533 3,688 Short t erm debt 765 316 400 Long t erm debt 2,831 3,216 3,288 (+) Lease L
Slide 30: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 31: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end. 2) As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that h
Slide 32: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 1Q'24 2Q'24 3Q'24 4Q'24 1Q'25 2Q'25 3Q'25 4Q'25 1Q'26 Revenue Oncosalud Peru 253 269 273 276 281 286 294 304 314 Healthcare Services Peru 241 255 255 245 263 269 279 273 281 Healthcare Services Colombia 349 37
Slide 33: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 33